Development of a Novel Immune Modulator Delivered via mRNA for Pediatric & Adult Solid Cancers: Pre-Clinical & Clinical Strategy
- USP6 (a de-ubiquitinase) has data in over 15 cancer types
- MER-101 (mRNA encoding USP6) is being studied in combination with checkpoint inhibitors in a humanized mouse model
- MER-101 is being developed for broad pediatric and adult indications including the rare pediatric Ewing sarcoma helping open a large adult market